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Abstract
Background The txt2stop trial has shown that mobile-
phone-based smoking cessation support doubles biochem-
ically validated quitting at 6 months. This study examines
the cost-effectiveness of smoking cessation support deliv-
ered by mobile phone text messaging.
Methods The lifetime incremental costs and benefits of
adding text-based support to current practice are estimated
from a UK NHS perspective using a Markov model. The
cost-effectiveness was measured in terms of cost per
quitter, cost per life year gained and cost per QALY
gained. As in previous studies, smokers are assumed to
face a higher risk of experiencing the following five dis-
eases: lung cancer, stroke, myocardial infarction, chronic
obstructive pulmonary disease, and coronary heart disease
(i.e. the main fatal or disabling, but by no means the only,
adverse effects of prolonged smoking). The treatment costs
and health state values associated with these diseases were
identified from the literature. The analysis was based on the
age and gender distribution observed in the txt2stop trial.
Effectiveness and cost parameters were varied in deter-
ministic sensitivity analyses, and a probabilistic sensitivity
analysis was also performed.
Findings The cost of text-based support per 1,000
enrolled smokers is £16,120, which, given an estimated 58
additional quitters at 6 months, equates to £278 per quitter.
However, when the future NHS costs saved (as a result of
reduced smoking) are included, text-based support would
be cost saving. It is estimated that 18 LYs are gained per
1,000 smokers (0.3 LYs per quitter) receiving text-based
support, and 29 QALYs are gained (0.5 QALYs per quit-
ter). The deterministic sensitivity analysis indicated that
changes in individual model parameters did not alter the
conclusion that this is a cost-effective intervention. Simi-
larly, the probabilistic sensitivity analysis indicated a
[90 % chance that the intervention will be cost saving.
Interpretation This study shows that under a wide variety
of conditions, personalised smoking cessation advice and
support by mobile phone message is both beneficial for
health and cost saving to a health system.
Keywords Smoking cessation aid  Economic
evaluation  Text message
JEL I18
Introduction
The txt2stop trial randomised 5,800 smokers aged 16 years or
older to personalised smoking cessation advice and support by
mobile phone message or to a control group [1]. Participants in
the intervention arm received five text messages per day for
the first 5 weeks and three per week for the next 26 weeks.
Participants in the control group received texts every two
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weeks related to the importance of trial participation. Mobile
phone text messaging smoking cessation support doubles
(10.7 vs 4.9 %) biochemically verified smoking cessation at
6 months (relative risk 2.20, 95 % CI 1.80–2.68 P \ 0.0001)
compared to a control group using any existing smoking
cessation support of their choice. The intervention is effective
in all socio-economic groups, and in younger and older
smokers [1]. A detailed description of the development of the
txt2stop intervention is reported elsewhere [2, 3].
Interventions to encourage smoking cessation must be
assessed not only for effectiveness but also in terms of value
for money [4]. Existing smoking cessation interventions that
have been shown to be cost effective (in a UK context a cost
per QALY gained of \£20,000) include group counselling,
one-to-one counselling, telephone counselling, and medica-
tions, such as nicotine replacement therapy and varenicline
[5]. To our knowledge, there are no previous cost-effective-
ness evaluations of smoking cessation interventions utilising
mobile devices. This study assesses the cost-effectiveness of
text-based support when added to the treatments used in the
control arm of the txt2stop trial. At randomisation, 818 par-
ticipants were using additional smoking cessation support:
82 % used medication (NRT, buproprion or varenicline), 4 %
used a telephone helpline, 3 % used group or individual
counseling, and 12 % used other support.
Methods
This analysis applied a cohort simulation model to determine
the cost-effectiveness of text-based support in addition to
current practice versus current practice alone. Current prac-
tice is defined as the mix of interventions currently available
in the UK to help people stop smoking (as represented in the
txt2stop trial). One in seven of the trial participants were
using additional smoking cessation support at randomisation
(82 % used nicotine replacement therapy, buproprion or
varenicline; 4 % a telephone helpline; 3 % group or individual
counselling; and 12 % used other support).
Model
This study uses a model adopted in previous economic evalu-
ations of smoking cessation interventions conducted in UK
from a health service perspective [5, 6]. The Markov state
transition model (Fig. 1) used in the study by Flack et al. [5] is
populated using the most recent UK data. At the start of the
analysis, the simulated population consists entirely of smokers.
A 6-month cycle is adopted, with transitions between smoking
status occurring every 6 months according to the probability of
remaining, in or moving to, one of three mutually exclusive
states: smoker, former smoker, and dead. In each cycle it is
assumed that both former and current smokers have a chance of
developing the five main health consequences of smoking: lung
cancer, stroke, myocardial infarction (MI), chronic obstructive
pulmonary disease (COPD), and coronary heart disease (CHD)
[7]. A lifetime horizon is chosen in order to calculate the
incremental cost of text-based support, and the life years (LY)
and quality adjusted life years (QALY) gained. This time
period is necessary to allow for the inclusion of all costs and
effects of the intervention. All costs are expressed in UK
pounds (£) in terms of financial year 2009–2010. Costs are
estimated from an NHS perspective and the discount rate used
is 3.5 % for cost and outcomes as per NICE guidance [8]. In
order to allow comparison with previous economic evaluations
of smoking cessation interventions in UK we have used the
same data sources as Flack et al. [5]; more recent data being
used where available.
Study population
The number of LYs and QALYs gained by text-based support,
and thus its cost-effectiveness, will depend on the initial age of
the smokers as smoking mainly causes health conditions that
need a long time period to develop after exposure to smoking.
To allow for this, the analysis is conducted separately for three
age groups: \30 years (30 % of the trial population),
30–40 years (31 %), and[40 years (39 %). The mean age for
each age group was 24, 35 and 48 years, respectively, based
on the txt2stop trial data. These values are adopted as the
starting age in the cohort models. The number of LYs and
QALYs gained also depends on the gender of the smokers. It is
well established that women live longer than men but with a
higher burden of disabilities [9]. In order to account for this,
the analysis is conducted for each age group separately for
men and for women. The overall results (number of life years,
QALY and disease costs) are calculated as a weighted average
of the results for the three age groups using the gender pro-
portions observed in the trial (male 55 %, female 45 %).
Probabilities
The relative risk of quitting at 6 months for text-based

















Fig. 1 Markov model
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P \ 0.0001), is applied to the quit rate at 6 months in the
control group (4.9 %) [1]. A 21 % relapse rate is assumed
between 6 and 12 months for both the control and the
treatment group [10]. A recent meta-analysis of 12 trials
estimates that there is no difference between control and
treatment groups in the relapse to smoking after 1 year of
cessation (OR 1.11, 95 % CI 0.78–1.59). Based on this
latter study, a lifetime relapse rate of 30 % among those
who have quit for 12 months is assumed in the model [11].
Failure to take account of the background quit rate would
lead to an overestimate of the effectiveness of text-based
support, since a number of the additional quitters would have
quit anyway in the future in the absence of test-based support.
The background quit rate is likely to vary across age groups.
The markedly higher proportion of ex-smokers among those
aged 55 and over might indicate a higher background quit rate
in this age group [12]. Also the background quit rate may be
increasing as more support for smoking cessation becomes
available. However, in the absence of good data, and fol-
lowing previous studies, a background quit rate of 2 % per
year is assumed for all smokers (with or without text-based
support) for all 6-month simulation cycles independently of
the age and gender of the smokers [13].
Mortality rate in the general population by age and gender
were retrieved from the Health Survey for England [12]. The
prevalence of smokers, never smokers and quitters by age and
gender in the UK population was obtained from the 2009
Office of National Statistics household survey [14]. The rel-
ative risk of dying of smokers versus never smokers and
quitters by age was retrieved from a study conducted by Doll
et al. [15]. These data were combined to calculate the prob-
ability of dying for a single individual in the cohort changes
within each cycle according to the individual age, gender and
smoking status (former smokers, smokers). As for previous
studies the formula used was the following:
Mortality rateag ¼ Mortality smokera  Prevalence of smokerag
 
þ Mortality former smokera  Prevalence of former smokerag
 
þ Mortality of never smokera  Prevalence of never smokerag
 
Where a is the age group and g is gender. The estimated
mortality rates used to populate the model are reported in
Table 3 of the ‘‘Appendix’’.
Similarly, the probability of experiencing smoking-
related diseases is estimated for each gender and age sep-
arately using the formula reported below (See Table 4
‘‘Appendix’’) [5]:
Disease prevalenceag ¼ Disease prevalence smokerag  Prevalence of smokerag
 
þ Disease prevalence of former smokerag  prevalence of former smokerag
 
þ Disease prevalence of never smokerag  Prevalence of never smokerag
 
As with previous studies we include overall mortality by
smoking status and did not consider disease-specific
mortality in order to avoid double counting. Diseases
within each cycle were assumed to be mutually exclusive
(within each 6 months individuals can experience only one
of the five diseases, survive with no disease or die). This
assumption is consistent with previous studies.
As in Flack et al. [5] and Raikou and McGuire [6], the
prevalence rates for lung cancer and COPD are taken from
Forman et al. [16] and Britton [17], respectively (See
‘‘Appendix’’). Prevalence of CHD, MI and stroke are
taken from the study by Allender et al. [18] (See
‘‘Appendix’’). The probability of developing lung cancer
by smoking status and gender comes from Peto et al. [19].
while the relative risks of the other smoking-related dis-
eases (CHD, MI, COPD and stroke) are from a study on
the health consequences of smoking conducted by the
Department of Health and Human Services [7] (See
‘‘Appendix’’).
Health state values
The health state values assigned to smoking-related dis-
eases and, in absence of these diseases, to smoking status
follow Flack et al. [5]. Diseases such as lung cancer, COPD
and stroke present several phases of disease progression.
For example, Tengs and Wallace [20] identify four health
state values according to the type of stroke: minor stroke,
moderate stroke, acute stroke requiring hospitalization and
major stroke. Similarly, health state values associated with
lung cancer are affected by the type of treatment under-
taken and the stage of the disease. However, to assign
different values according to the severity level of the dis-
ease requires knowledge of the proportion of smokers and
previous smokers in each of these states. Lacking these
data, simple averages of the available values for each of the
diseases are used as in previous evaluations [5]. The values
used for each disease are: 0.58 for lung cancer, 0.48 for
stroke, 0.80 for CHD and MI (the estimate for MI is an
average of the values reported by Tengs and Wallace [20]
for MI of different disease severities), and 0.73 for COPD
(an average of the different values for COPD severity
estimated by Rutten-van Molken et al. [21]). Finally, dif-
ferent values are assigned to smokers (0.75) and former
smokers (0.78) as reported in the UK study conducted by
Tillman and Silcock [22].
Costs
The cost of text-based support per smoker is the sum of
three elements: the cost of enrolling smokers (including the
cost of collecting information about age, gender educa-
tion etc.), the cost of text messages (including the cost of
setting a short code), and any royalty paid for use of the
intervention.
The cost-effectiveness of smoking
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Smokers wishing to use text-based support can register
directly online or by SMS. The cost of web site mainte-
nance is assumed to be zero in this analysis because the
same site is used for other types of smoking cessation
services. The cost of text messages per smoker, £16.12,
includes the cost of setting up a short code (£0.06/partici-
pant), and the cost of sending the messages (£14.51). The
lack of data on the proportion of smokers and former
smokers at each disease stage does not allow consideration
of how costs vary according to the severity of these dis-
eases. Average cost estimates were used in the absence of
these data. For example, in the case of stroke the estimated
annual total cost of stroke in UK was divided by the
number of people who experienced the disease [5]. The
annual costs assigned to each of the smoking-related dis-
eases are lung cancer (£5,921), stroke (£2,218), MI
(£2,341), COPD (£997), and CHD (£1,144) [23–27]. All
the costs are inflated to 2009–2010 prices using the hospital
and community health services price index.
Sensitivity analysis
Deterministic sensitivity analyses and a probabilistic sen-
sitivity analysis (PSA) were performed to assess parameter
uncertainty. The impact of variations in the effectiveness of
text-based support on cost-effectiveness was investigated
by assuming that the relative risk ranged between 1.80 and
2.68 (the 95 % confidence interval around the effect
observed in the txt2stop trial). Further analyses were per-
formed to estimate the cost-effectiveness of text-based
support for different lifetime relapse rates, 21 %, used as
the lower value (reported by McGhan and Smith [28]) and
50 % (the highest value reported in the literature for the
relapse rate between 6 and 12 months [29]).
The lower value for the background smoking cessation
rate in the one-way sensitivity analysis (1.2 %) is the historic
rate over the past 40 years in England, while the upper value
(2.8 %) is the highest background cessation rate suggested by
West [13]. In the base case analysis, advertising cost is
assumed to be zero and it is assumed that 100 % of smokers
will register online. It is not known whether the NHS would
advertise the intervention using pre-existing channels at rel-
atively low marginal cost or whether advertising on the radio/
internet/TV will be utilised. In order to account for this ele-
ment of uncertainty, the incremental cost-effectiveness of
text-based support is estimated assuming an intervention cost
ranging from £15 per smoker (assuming that all the smokers
register on-line, no crave messages and 10,000 users per short
code) to £60.22 (assuming an additional advertising cost of
£44, as observed in the txt2stop trial). These figures are used
for illustrative purposes. Given large-scale implementation of
text-based support, advertising costs are likely to be lower
than those incurred when advertising the opportunity to
participate in a smoking cessation trial. There are some
additional costs which could arise in practice, such as royalty
payments for the use of the IT program for the text-based
support intervention, and management costs to co-ordinate
the provision of the service. Both of these would be influ-
enced strongly by the scale of text-based support were it to be
implemented, the larger the scale the lower the cost per
smoker. To investigate the impact of these potential addi-
tional costs, the analysis was re-run with additional costs of
£1 and £35 per smoker enrolled.
A second order Monte Carlo simulation with 1,000
iterations was used to assess the influence of parameter
uncertainty on the study results. Parameters were consid-
ered independent. Following suggested practice, a lognor-
mal distribution was assigned to relative risks, and beta
distributions were assigned to the lifetime relapse rate,
baseline quit rate and health state values [30] (See
‘‘Appendix’’). A gamma distribution was adopted for unit
costs. Each variable estimate was derived from its proba-
bility distribution (See ‘‘Appendix’’).
Cost-effectiveness acceptability curves (CEACs) were
constructed to represent uncertainty regarding the param-
eters of the model. The net monetary benefit from text-
based support was estimated for each simulation using the
following equation:
Net monetary benefit ¼ k  ðET2S  ECPÞ  ðCOSTT2S
 COSTCPÞ
where: k represents the ‘‘willingness to pay’’ per QALY
gained, (ET2S - ECP) is the incremental effectiveness
(number of QALY gained) of text-based support, and
(COSTT2S - COSTCP) is the incremental cost of text-
based support. CEACs plot the proportion of simulations
for which text-based support is cost-effective for a will-
ingness to pay per QALY from £0 to £4,000.
Results
The cost of text-based support per 1,000 enrolled smokers
is £16,120, which, given an estimated 58 additional quitters
at 6 months, equates to £278 per quitter. However, once the
avoided future NHS costs (as a result of reduced smoking)
are taken into account, text-based support would be cost
saving as observed in Table 1 for all three age groups. It is
estimated that 18 LYs are gained per 1,000 smokers
receiving text-based support and 29 QALYs are gained (of
which 27 are attributable to a reduction in smoking-related
diseases).
One-way sensitivity analyses are reported (for all
smokers) in Table 2. If a much lower estimate of the
treatment effect is assumed, other parameters remaining
the same, text-based support continues to be cost saving
C. Guerriero et al.
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while at the same time producing gains in LYs and QA-
LYs. Varying the relapse rate and the baseline quit rate
does not change the finding that text-based support is
health improving and cost saving. If a higher intervention
cost is assumed and advertising costs are similar to those
observed in the txt2stop trial, then the incremental cost-
effectiveness would be £141 per LY gained and £89 per
QALY gained. If a management cost of £35 is charged per
participant the intervention is still cost-saving assuming a
health service perspective.
The PSA, in which distributions are assumed to reflect
uncertainty about assumptions regarding the relative risk,
the lifetime relapse rate, the baseline quit rate, and the unit
costs, implies that there is a [90 % chance that the inter-
vention will be cost saving (see Fig. 2).
Discussion
This economic evaluation shows that text-based smoking
cessation support (provided in addition to the existing
range of smoking cessation services) produces health
benefits and reduces health service costs. Moreover, sen-
sitivity analyses indicate that text-based support remains
cost effective under a wide range of alternative
assumptions.
The primary strength of this evaluation of text-based
support for smoking cessation is that it uses a valid and
precise estimated treatment effect. A further strength is that
the analysis is based on an established economic model.
Nonetheless, a number of limitations must be considered
when interpreting the study findings. As with previous
economic evaluations this study potentially undervalues
the benefits of text-based support as a smoking cessation
intervention in that it does not take into account the effects
of reduced passive smoking, nor does it account for short-
term effects (e.g. reduction in respiratory problems) asso-
ciated with smoking cessation [5, 6, 31, 32], or a wide
range of other less common smoking-related diseases [33].
For this reason it also underestimates the potential savings
from the intervention because it does not account for the
cost (differences) of complication-free health states
(smokers without complications are likely to cost more to
the NHS rather than former smokers without complica-
tions). Another limitation of this study is that the costs and
the health state values associated with different smoking-
related diseases are averages across different severity
levels. This is because of the lack of information on the
proportion of smokers, quitters and never smokers experi-
encing the different severity levels.
As always, there is uncertainty regarding the values of
the various model parameters. The likely cost of text-based
Table 1 Incremental costs, life years (LYs) gained and quality-adjusted life years (QALYs) gained per 1,000 enrollees
25 year-olda 35 year-olda 48 year-olda Weighted averageb
Cost without text-based support £3,177,185 £4,690,512 £7,446,703 £5,299,712
Cost with text-based support £3,166,119 £4,660,193 £7,374,176 £5,258,203
LYs without text-based support 23,546 21,591 18,244 20,859
LYs with text-based support 23,555 21,607 18,271 20,877
QALYs without text-based support 17,772 16,136 13,341 15,528
QALYs with text-based support 17,792 16,163 13,379 15,557
Incremental cost -£11,066 -£30,320 -£74,214 -£41,509
Incremental LYs 9 16 27 18
Incremental QALYs 20 27 38 29
a These ages represent the \30 years, 30–40 years and [40 years groups in the simulation
b Weights are from the txt2stop trial
Table 2 One-way sensitivity analyses
Incremental cost per LY Incremental cost per QALY
Relative risk continuous abstinence at 6 months (1.80:2.68) NA:NAa NA:NA
Lifetime relapse rate (21:50 %) NA:NA NA:NA
Baseline quit rate (1.2:2.8 %) NA:NA NA:NA
Cost of intervention per smoker (£6.70:£62.30) NA:£141 NA:£89
Royalty, management cost per smoker (£1:£35) NA:NA NA:NA
a Not applicable because health improving and cost saving
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support if it were to be implemented widely would depend,
in part, on the numbers using the service, since this may
influence the cost of text messages and royalty payments.
Finally, this study did not account for non-smoking-
related medical costs. A recent study conducted in the
Netherlands showed that, while smoking cessation inter-
ventions reduce the number of smokers and the medical
cost of treating a range of medical conditions, such as
stroke, cardiovascular diseases etc., associated with
smoking, former smokers have higher lifetime medical
costs because they survive longer [34, 35]. If a perspective
were adopted where non-smoking-related medical costs
were to be considered, the estimated savings associated
with text-based support will have been over-estimated.
Care must be taken when comparing the cost per quitter,
cost per LY gained and cost per QALY gained reported in
this study with those from other studies because incre-
mental cost-effectiveness will depend, in part, on the
comparator. In this study the comparator was current
practice, here defined as the mix of smoking cessation
interventions accessed by those in the control arm of the
txt2stop trial. The results of this study are consistent with
previous economic evaluations that show that smoking
cessation interventions are highly cost effective. The cost
per quitter for text-based support appears lower than for
some other smoking cessation interventions. For example,
the cost per quitter for telephone counselling (in
2009–2010 prices) is £895, for minimal counselling plus
NRT is £955, and for intensive counselling plus NRT is
£1,621 [36]. The Flack et al. [5] study, which used the
same model adopted in the present analysis, shows that
among a range of interventions (combinations of self-help
materials, nicotine patches, individual counselling and
nicotine replacement therapy) the only intervention that
was cost-increasing compared to brief GP advice was brief
advice plus self help material plus nicotine replacement
therapy (£1,074 per QALY, 2009–2010 prices). A sub-
sequent study, using the same methodological assumptions,
that evaluated the cost-effectiveness of a mass media
campaign to prevent the uptake of smoking among young
people, found using a range of sensitivity analyses com-
pared to no intervention that the cost per QALY was never
more than £1,142 per QALY (2009–2010 prices) [6].
The intervention is highly cost effective given the cost-
effectiveness thresholds generally applied in the UK, and
on the basis of these results the txt2stop mobile phone text
messaging intervention should be considered as an addition
to existing smoking cessation services. The self-reported
smoking cessation results reported in the txt2stop trial are
similar to those reported in previous trials of smoking
cessation support delivered via mobile phone text mes-
saging in New Zealand [3]. It would be technically rela-
tively easy to scale up the intervention for delivery
internationally, and it is likely that the intervention would
be cost effective, at least in other high income settings that
are likely to have similarly high cost savings as a result of
reductions in smoking-related diseases.
Further research should establish the effects and cost-
effectiveness of text-based smoking cessation support in
other settings, such as low- and middle-income countries.
Research is needed to evaluate the cost-effectiveness of
text-based support, including the effects of smoking ces-
sation on short-term health outcomes, and for long term
smokers versus newer smokers.
This study clearly indicates that text-based support is
likely to be a cost-effective means of encouraging smoking
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Appendix
See Tables 3, 4, 5, 6.
Table 3 Mortality rate per 1,000 by age and smoking status [15]
Age Current smoker Former smoker Non-smoker
35–44 2.8 2 1.6
45–54 8.1 4.9 4
55–64 20.3 13.4 9.5
65–74 47 31.6 23.7
75–84 106 77.3 67.4
85? 218.7 179.7 168.6
Table 4 Relative risks (RRs) of chronic obstructive pulmonary dis-
ease (COPD), stroke, myocardial infarction (MI), lung cancer and
coronary heart disease (CHD) by gender and smoking status [7]
Current smoker Former smoker Non smoker
COPD
Women 1 0.84 0.68
Men 1 0.96 0.92
Stroke
Women/men 1.37 1.11 1
MI
Women 1.6 1.11 1
Men 2.76 1.05 1
Lung cancer
Women 1 0.44 0.03
Men 1 0.21 0.05
CHD
Women/men 3.12 1.55 1
Table 5 Six-month probability of CHD, lung cancer, MI, stroke and









Female Female Male Male
CHD
16–24 0.0000 0.0000 0.0000 0.0000
25–34 0.0000 0.0000 0.0000 0.0000
35–44 0.0091 0.0045 0.0083 0.0041
45–54 0.0338 0.0166 0.0335 0.0165
55–64 0.1213 0.0583 0.1075 0.0519
65–74 0.2654 0.1218 0.2456 0.1135
75? 0.3674 0.1622 0.3234 0.1452
MI
16–24 0.0000 0.0000 0.0000 0.0000
25–34 0.0000 0.0000 0.0000 0.0000
35–44 0.0000 0.0000 0.0000 0.0000
45–54 0.0000 0.0000 0.0000 0.0000
55–64 0.0730 0.0287 0.0465 0.0320
65–74 0.0772 0.0303 0.0485 0.0334
75? 0.1562 0.0597 0.0903 0.0617
COPD
16–24 0.0045 0.0053 0.0065 0.0055
25–34 0.0044 0.0053 0.0062 0.0052
35–44 0.0045 0.0053 0.0063 0.0053
45–54 0.0044 0.0053 0.0063 0.0053
55–64 0.0045 0.0053 0.0061 0.0052
65–74 0.0225 0.0269 0.0315 0.0264
75? 0.0457 0.0546 0.0647 0.0541
Lung cancer
16–24 0.0000 0.0000 0.0000 0.0000
25–34 0.0000 0.0000 0.0000 0.0000
35–44 0.0000 0.0000 0.0000 0.0000
45–54 0.0021 0.0009 0.0020 0.0009
55–64 0.0024 0.0011 0.0018 0.0008
65–74 0.0138 0.0061 0.0108 0.0047
75? 0.0155 0.0068 0.0115 0.0050
Stroke
16–24 0.0000 0.0000 0.0000 0.0000
25–34 0.0000 0.0000 0.0000 0.0000
35–44 0.0020 0.0014 0.0020 0.0014
45–54 0.0082 0.0057 0.0082 0.0057
55–64 0.0143 0.0099 0.0143 0.0099
65–74 0.0552 0.0380 0.0552 0.0380
75? 0.0997 0.0680 0.0997 0.0680
The cost-effectiveness of smoking
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